Fibroblasts were treated with an inhibitor in parallel to dKD to test whether there is a causal relationship between the increased TGFβ1 expression and myofibroblast differentiation during XYLT1/XYLT2 dKD. Here, TGFB1 is linked to diabetic kidney disease.